Needham Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.